In selected cases meeting NICE criteria for obesity pharmacotherapy (e.g., semaglutide 2.4mg/Wegovy with BMI 35 kg/m with comorbidities or 30 kg/m with weight-related comorbidities, prescribed through specialist weight management services) or bariatric surgery, these interventions may be considered, with specialist input to ensure safe implementation alongside lymphoedema management strategies
Finally, the absence of gut microbiome and hepatic metabolism data limits mechanistic interpretation, particularly for diet-responsive metabolites such as coumarin
Vincent, K., Kennedy, S., & Stratton, P
GLP-1 compounds may help lower triglycerides in metabolically compromised individuals through weight loss and improved insulin sensitivity, but individual responses vary based on baseline status and genetic factors